Rite Aid (NYSE:RAD) has been one of Wall Street's top performers this year as the company's restructuring plan has returned it to profitability.

However, Rite Aid's plans to improve working capital and profitability by outsourcing generic drug purchasing to McKesson (NYSE:MCK) hit a snag last quarter that weighed on profit.

In the following slideshow, I've included 18 quotes from Rite Aid's management that provide insight into five subjects: the McKesson headwind, Obamacare's impact, expansion plans, health care clinics, and guidance for the remainder of this year.

Even Rite Aid may struggle to keep pace with this stock
The best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends McKesson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.